Developer docs
API playgroundTry for free, no card

Search company profiles

Protokinetix

Full company profile

uuid000393v

Namestring
Protokinetix
Legal namestring
ProtoKinetix, Incorporated
Company typeenum
Public
Founded yearint
2002
Descriptiontext

ProtoKinetix is a clinical-stage biomedical company founded in 2002 and publicly traded on OTC Markets under the ticker PKTX, headquartered in Dalton and Marietta, Ohio. The company develops a single proprietary platform technology, AAGP® (Anti-Aging Glycopeptide, molecule PKX-001), a synthetic 580.96-Dalton analog of naturally occurring antifreeze glycoproteins that protects living cells from inflammation, oxidative stress, UV and temperature extremes, and protease degradation. The molecule's compact size, relative to natural AFGPs in the 2,600-24,000 Dalton range, enables passage through cell junctions and capillaries, which is the core technical differentiator.

The company has organized its pipeline around four therapeutic and industrial application areas — ophthalmology, dermatology, transplant support, and biomanufacturing — with the lead program, islet cell transplantation for Type 1 diabetes, currently in Phase 2 at the University of Alberta under principal investigator Dr. James Shapiro. Preclinical and research collaborations are conducted with the University of British Columbia (macular degeneration and hematopoietic stem cell recovery) and Dalhousie University (cardiovascular), with GMP manufacturing handled by AmbioPharm in South Carolina and commercialization support for the dry eye disease program provided by IQVIA.

ProtoKinetix has no commercial products on the market and is pre-revenue; the stated business model combines patent licensing to pharmaceutical companies in each therapeutic vertical with potential future OTC/prescription consumer eye drops and skin creams. Capital has been raised through a long series of small SEC exempt offerings, and the company states it is debt-free. The company is in a leadership transition: long-tenured CEO Clarence E. Smith passed away in November 2025 and was succeeded by Michael Guzzetta as Chairman, President, CEO and CFO.

Short descriptiontext

ProtoKinetix is a pre-revenue, clinical-stage biotech that develops AAGP®, a proprietary synthetic glycopeptide used to protect living cells in ophthalmology, dermatology, transplant, and biomanufacturing applications, targeting pharmaceutical licensees and research partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMarietta, United States
HQ citystring
Marietta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell survival therapeutics, anti-aging glycopeptide, regenerative medicine research, clinical stage biotechnology, islet cell transplantation
Industry4 codes
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing Royalties
TypeLicensing Royalties
Description

Licensing the patent to pharmaceutical companies in each market segment (ophthalmology, dermatology, transplants, biomanufacturing). The company has stated willingness to license to multiple companies so all patients can experience the benefits of AAGP®.

protokinetix.com
2Product Sales
TypeOne Time License
Description

Direct sales of prescription and over-the-counter eye drops and skin creams containing AAGP®.

protokinetix.com
3Securities Offering
TypeSubscription Recurring
Description

Exempt offering of securities to raise capital for ongoing research and development activities.

sec.gov
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ProtoKinetix develops and commercializes AAGP® (Anti-Aging Glycopeptide), a proprietary synthetic glycopeptide molecule engineered to protect human cells from stress, inflammation, temperature extremes, and cell death factors. The molecule is being developed for therapeutic applications in ophthalmology (retinal cell transplants, dry eye disease, macular degeneration), dermatology (anti-inflammation, UV/burn recovery), transplant support (islet cell transplants for Type 1 diabetes, whole organ viability), and biomanufacturing (cell preservation during biologics production).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 55% average increase in cell survival across various stress conditions
+4 more records
Product overview1 text field

ProtoKinetix is a clinical-stage biomedical company developing AAGP®, a proprietary synthetic anti-aging glycopeptide molecule (580.96 Daltons). The company's product portfolio centers on this core molecule with multiple therapeutic applications spanning four areas: ophthalmology (retinal cell transplantation, dry eye disease), dermatology (inflammation protection, UV/burn recovery), transplant support (islet cells for Type 1 diabetes, whole organ viability), and biomanufacturing (biologics production, cell preservation). The lead drug product, PKX-001, is currently in Phase 1/2 clinical trials for Type 1 diabetes islet cell transplantation at the University of Alberta. All products are investigational and not approved for commercial distribution.

Product and service1 record
1AAGP® (Anti-Aging Glycopeptide)
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Contract research organization that conducted preclinical ocular safety studies in small and large animals, and preclinical ocular efficacy studies for ophthalmology applications.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Contract research organization that conducted preclinical ocular safety study in large animals for ophthalmology applications.

Strategic tierMajorTypeImplementation/ SI/ Consulting PartnerAnnounced on2020-01-01
Description

Strategic partnership with IQVIA to execute go-forward strategy for dry eye disease clinical trial and commercialization program. IQVIA provides clinical trial execution and commercialization expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Cardiovascular research program partnership studying the effects of AAGP® on heart tissue and cardiovascular health. Dr. Pulinilkunnil serves as principal investigator.

5University of British Columbia (Dr. Kelly McNagny)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Enhanced biological production and hematopoietic stem cell recovery research partnership focused on cellular immunology and stem cell preservation.

protokinetix.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Clinical research partnership for Phase 1 and Phase 2 clinical trials of AAGP® (PKX-001) in islet cell transplants for Type 1 diabetes treatment. Dr. James Shapiro serves as principal investigator and leads the Edmonton Protocol research.

7University of British Columbia (Dr. Kevin Gregory-Evans)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

Macular degeneration cell therapy program partnership focused on retinal cell replacement therapy. Dr. Gregory-Evans serves as lead macular researcher and is testing AAGP®-treated cells for continued development into retinal cells.

protokinetix.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2010-01-01
Description

Manufacturing partner for Good Manufacturing Practice (GMP) processing of AAGP® and preliminary toxicology assessment. Located in Beech Island, SC with capability for large-scale bioproduct validation.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Cryoport provides integrated temperature-controlled logistics and cryopreservation services for the cell-therapy industry, competing in the same cell-survival/cell-preservation value chain as ProtoKinetix's biomanufacturing and transplant applications.

TypeBroad incumbent
Description

Lonza is a global contract development and manufacturing organization with a major cell-and-gene-therapy services business, relevant as both a potential biomanufacturing partner and competitor in ProtoKinetix's biomanufacturing vertical.

TypeEmerging player
Description

CRISPR Therapeutics is a clinical-stage gene-editing company developing ex vivo and in vivo cell therapies, broadly comparable to ProtoKinetix as a next-generation cell-therapy platform developer.

TypeDirect peer
Description

BioLife Solutions develops cryopreservation and cell-storage media used by cell-therapy developers, directly comparable to ProtoKinetix's cell-survival technology for transplant and biomanufacturing applications.

5Sigilon Therapeutics
TypeEmerging player
Description

Sigilon develops encapsulated cell therapies for chronic diseases, a therapeutic approach that intersects with ProtoKinetix's islet-cell encapsulation and Type 1 diabetes strategy.

TypeBroad incumbent
Description

Sartorius supplies bioprocessing equipment and consumables used in cell therapy and biologics production, overlapping with the manufacturing infrastructure supporting ProtoKinetix's biomanufacturing application area.

TypeBroad incumbent
Description

Vertex has advanced its VX-880 stem cell-derived therapy into clinical trials for Type 1 diabetes, positioning it as the dominant large-cap player in ProtoKinetix's lead T1D islet-cell indication.

TypeDirect peer
Description

BlueRock Therapeutics is a leading iPSC-derived cell therapy developer (acquired by Bayer), pursuing regenerative medicine applications overlapping directly with ProtoKinetix's pluripotent-stem-cell transplantation platform.

TypeEmerging player
Description

Sana Biotechnology is a clinical-stage cell engineering company focused on regenerative medicine and cell therapy, sharing ProtoKinetix's regenerative-cell platform ambition across multiple disease areas.

10ViaCyte
TypeDirect peer
Description

ViaCyte is a clinical-stage cell-therapy developer focused on stem cell-derived islet cell replacement for Type 1 diabetes, the same lead indication targeted by ProtoKinetix's PKX-001 program with Dr. James Shapiro.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds30 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Protokinetix

Biopharmaceuticalsprotokinetix.com

ProtoKinetix is a pre-revenue, clinical-stage biotech that develops AAGP®, a proprietary synthetic glycopeptide used to protect living cells in ophthalmology, dermatology, transplant, and biomanufacturing applications, targeting pharmaceutical licensees and research partners.

What Protokinetix does

ProtoKinetix is a clinical-stage biomedical company founded in 2002 and publicly traded on OTC Markets under the ticker PKTX, headquartered in Dalton and Marietta, Ohio. The company develops a single proprietary platform technology, AAGP® (Anti-Aging Glycopeptide, molecule PKX-001), a synthetic 580.96-Dalton analog of naturally occurring antifreeze glycoproteins that protects living cells from inflammation, oxidative stress, UV and temperature extremes, and protease degradation. The molecule's compact size, relative to natural AFGPs in the 2,600-24,000 Dalton range, enables passage through cell junctions and capillaries, which is the core technical differentiator.

The company has organized its pipeline around four therapeutic and industrial application areas — ophthalmology, dermatology, transplant support, and biomanufacturing — with the lead program, islet cell transplantation for Type 1 diabetes, currently in Phase 2 at the University of Alberta under principal investigator Dr. James Shapiro. Preclinical and research collaborations are conducted with the University of British Columbia (macular degeneration and hematopoietic stem cell recovery) and Dalhousie University (cardiovascular), with GMP manufacturing handled by AmbioPharm in South Carolina and commercialization support for the dry eye disease program provided by IQVIA.

ProtoKinetix has no commercial products on the market and is pre-revenue; the stated business model combines patent licensing to pharmaceutical companies in each therapeutic vertical with potential future OTC/prescription consumer eye drops and skin creams. Capital has been raised through a long series of small SEC exempt offerings, and the company states it is debt-free. The company is in a leadership transition: long-tenured CEO Clarence E. Smith passed away in November 2025 and was succeeded by Michael Guzzetta as Chairman, President, CEO and CFO.

Protokinetix firmographics

Firmographics
Name
Protokinetix
Legal name
ProtoKinetix, Incorporated
Website
https://protokinetix.com
Company type
Public
Founded year
2002
Operating status
Operating
Headcount range
1–10 employees
Short description
ProtoKinetix is a pre-revenue, clinical-stage biotech that develops AAGP®, a proprietary synthetic glycopeptide used to protect living cells in ophthalmology, dermatology, transplant, and biomanufacturing applications, targeting pharmaceutical licensees and research partners.
Ownership category
akta.pro rank

Protokinetix industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Cell survival therapeutics
  • Anti-aging glycopeptide
  • Regenerative medicine research
  • Clinical stage biotechnology
  • Islet cell transplantation

Where Protokinetix is headquartered

Location

Headquarters

HQ city
Marietta
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Protokinetix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing Royalties: Licensing the patent to pharmaceutical companies in each market segment (ophthalmology, dermatology, transplants, biomanufacturing). The company has stated willingness to license to multiple companies so all patients can experience the benefits of AAGP®.
  2. Product Sales: Direct sales of prescription and over-the-counter eye drops and skin creams containing AAGP®.
  3. Securities Offering: Exempt offering of securities to raise capital for ongoing research and development activities.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels9 records

Protokinetix product offering

Product offering

Core offering

ProtoKinetix develops and commercializes AAGP® (Anti-Aging Glycopeptide), a proprietary synthetic glycopeptide molecule engineered to protect human cells from stress, inflammation, temperature extremes, and cell death factors. The molecule is being developed for therapeutic applications in ophthalmology (retinal cell transplants, dry eye disease, macular degeneration), dermatology (anti-inflammation, UV/burn recovery), transplant support (islet cell transplants for Type 1 diabetes, whole organ viability), and biomanufacturing (cell preservation during biologics production).

Product overview

ProtoKinetix is a clinical-stage biomedical company developing AAGP®, a proprietary synthetic anti-aging glycopeptide molecule (580.96 Daltons). The company's product portfolio centers on this core molecule with multiple therapeutic applications spanning four areas: ophthalmology (retinal cell transplantation, dry eye disease), dermatology (inflammation protection, UV/burn recovery), transplant support (islet cells for Type 1 diabetes, whole organ viability), and biomanufacturing (biologics production, cell preservation). The lead drug product, PKX-001, is currently in Phase 1/2 clinical trials for Type 1 diabetes islet cell transplantation at the University of Alberta. All products are investigational and not approved for commercial distribution.

Differentiator

Problem solved

Functional benefit

Products and services

  • AAGP® (Anti-Aging Glycopeptide)

Quantifiable outcome

  • 55% average increase in cell survival across various stress conditions
  • +4 more outcomes

Companies that use Protokinetix

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Protokinetix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Protokinetix partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor, major and core.

  • EyeCrominorStrategic or Co-development Partner · 1 January 2022Contract research organization that conducted preclinical ocular safety studies in small and large animals, and preclinical ocular efficacy studies for ophthalmology applications.
  • Charles RiverminorStrategic or Co-development Partner · 1 January 2022Contract research organization that conducted preclinical ocular safety study in large animals for ophthalmology applications.
  • IQVIAmajorImplementation/ SI/ Consulting Partner · 1 January 2020Strategic partnership with IQVIA to execute go-forward strategy for dry eye disease clinical trial and commercialization program. IQVIA provides clinical trial execution and commercialization expertise.
  • Dalhousie University (Dr. Thomas Pulinilkunnil)coreStrategic or Co-development Partner · 1 January 2018Cardiovascular research program partnership studying the effects of AAGP® on heart tissue and cardiovascular health. Dr. Pulinilkunnil serves as principal investigator.
  • University of British Columbia (Dr. Kelly McNagny)coreStrategic or Co-development Partner · 1 January 2018Enhanced biological production and hematopoietic stem cell recovery research partnership focused on cellular immunology and stem cell preservation.
  • University of Alberta (Dr. James Shapiro)coreStrategic or Co-development Partner · 1 January 2017Clinical research partnership for Phase 1 and Phase 2 clinical trials of AAGP® (PKX-001) in islet cell transplants for Type 1 diabetes treatment. Dr. James Shapiro serves as principal investigator and leads the Edmonton Protocol research.
  • University of British Columbia (Dr. Kevin Gregory-Evans)coreStrategic or Co-development Partner · 1 January 2016Macular degeneration cell therapy program partnership focused on retinal cell replacement therapy. Dr. Gregory-Evans serves as lead macular researcher and is testing AAGP®-treated cells for continued development into retinal cells.
  • AmbioPharmcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2010Manufacturing partner for Good Manufacturing Practice (GMP) processing of AAGP® and preliminary toxicology assessment. Located in Beech Island, SC with capability for large-scale bioproduct validation.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Protokinetix competitors and assessment

Company assessment

Broad incumbents

  • Cryoport: Cryoport provides integrated temperature-controlled logistics and cryopreservation services for the cell-therapy industry, competing in the same cell-survival/cell-preservation value chain as ProtoKinetix's biomanufacturing and transplant applications.
  • Lonza Group: Lonza is a global contract development and manufacturing organization with a major cell-and-gene-therapy services business, relevant as both a potential biomanufacturing partner and competitor in ProtoKinetix's biomanufacturing vertical.
  • Sartorius AG: Sartorius supplies bioprocessing equipment and consumables used in cell therapy and biologics production, overlapping with the manufacturing infrastructure supporting ProtoKinetix's biomanufacturing application area.
  • Vertex Pharmaceuticals: Vertex has advanced its VX-880 stem cell-derived therapy into clinical trials for Type 1 diabetes, positioning it as the dominant large-cap player in ProtoKinetix's lead T1D islet-cell indication.

Emerging players

  • CRISPR Therapeutics: CRISPR Therapeutics is a clinical-stage gene-editing company developing ex vivo and in vivo cell therapies, broadly comparable to ProtoKinetix as a next-generation cell-therapy platform developer.
  • Sigilon Therapeutics: Sigilon develops encapsulated cell therapies for chronic diseases, a therapeutic approach that intersects with ProtoKinetix's islet-cell encapsulation and Type 1 diabetes strategy.
  • Sana Biotechnology: Sana Biotechnology is a clinical-stage cell engineering company focused on regenerative medicine and cell therapy, sharing ProtoKinetix's regenerative-cell platform ambition across multiple disease areas.

Direct peers

  • BioLife Solutions: BioLife Solutions develops cryopreservation and cell-storage media used by cell-therapy developers, directly comparable to ProtoKinetix's cell-survival technology for transplant and biomanufacturing applications.
  • BlueRock Therapeutics: BlueRock Therapeutics is a leading iPSC-derived cell therapy developer (acquired by Bayer), pursuing regenerative medicine applications overlapping directly with ProtoKinetix's pluripotent-stem-cell transplantation platform.
  • ViaCyte: ViaCyte is a clinical-stage cell-therapy developer focused on stem cell-derived islet cell replacement for Type 1 diabetes, the same lead indication targeted by ProtoKinetix's PKX-001 program with Dr. James Shapiro.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Protokinetix social profiles

Digital presence

Protokinetix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Protokinetix leadership team

Management profile

Number of profiles

Profiles8 records

Protokinetix funding detail

Funding detail

Funding overview

Funding rounds30 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Protokinetix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Protokinetix

What does Protokinetix do?

ProtoKinetix develops and commercializes AAGP® (Anti-Aging Glycopeptide), a proprietary synthetic glycopeptide molecule engineered to protect human cells from stress, inflammation, temperature extremes, and cell death factors. The molecule is being developed for therapeutic applications in ophthalmology (retinal cell transplants, dry eye disease, macular degeneration), dermatology (anti-inflammation, UV/burn recovery), transplant support (islet cell transplants for Type 1 diabetes, whole organ viability), and biomanufacturing (cell preservation during biologics production).

Is Protokinetix a public or private company?

Protokinetix is a public company. It is classified as public and is currently operating.

When was Protokinetix founded?

Protokinetix was founded in 2002. It employs 1 to 10 people.

Where is Protokinetix based?

Protokinetix is headquartered in Marietta, United States, in the North America region.

How does Protokinetix make money?

Three revenue lines are on record. Licensing Royalties are the primary driver. The others are product Sales and securities Offering.

Who are Protokinetix's main competitors?

Broad incumbents on record are Cryoport, Lonza Group, Sartorius AG and Vertex Pharmaceuticals. Emerging players are CRISPR Therapeutics, Sigilon Therapeutics and Sana Biotechnology. Direct peers are BioLife Solutions, BlueRock Therapeutics and ViaCyte.

Does Protokinetix have an API?

No public API is recorded for Protokinetix.

What industry is Protokinetix in?

Protokinetix's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingProtoKinetix delays third-quarter report as financial statement preparation takes longerProtoKinetix delayed its Form 10-Q for the quarter ended September 30, 2026, beyond the November 16, 2026, deadline, citing incomplete financial statement preparation and an auditor needing more time. The company expects to file within five calendar days of the original deadline, and its June 30, 2026, 10-Q remains unfiled.BloombergKeith R Brunt, Protokinetix Inc: Profile and Biography - Bloomberg MarketsThe article profiles Dr. Keith R Brunt, President of Protokinetix Inc., on Bloomberg Markets. It provides information about Bloomberg's services, products, and corporate details but does not mention a specific event involving the company.SecSEC FORM DProtoKinetix, Inc. filed an amended Form D with the SEC to increase its total exempt securities offering amount to $211,000 USD. The company, based in Dalton, Ohio, is conducting this equity offering under Rule 506(b) exemptions.SecSEC FORM DProtoKinetix, Inc. filed a Form D with the U.S. Securities and Exchange Commission to announce an exempt securities offering under Rule 506(b). The filing indicates a total offering amount of $100,000, with $50,000 already sold to four investors as of March 29, 2024. This regulatory submission serves as a formal notice of the private placement for equity securities.SecSEC FORM DProtoKinetix, Inc. filed a Form D with the SEC for an exempt securities offering under Rule 506(b). The company raised $135,000 of a $200,000 target from three investors as of December 26, 2023. The filing discloses executive officers and indicates the offering is intended to last less than one year.SecSEC FORM DProtoKinetix, Inc. filed a Form D with the U.S. Securities and Exchange Commission on April 16, 2024, notifying regulators of an exempt securities offering under Rule 506(b). The company has raised $35,000 so far toward a total offering target of $100,000, with sales commencing on March 29, 2024.SecSEC FORM DProtoKinetix, Inc. filed a Form D with the Securities and Exchange Commission to announce an exempt securities offering under Rule 506(b) starting on December 26, 2023. The company is raising up to $200,000 in equity, having sold $110,000 worth of securities to one investor as of the filing date. This routine regulatory disclosure represents a minor capital raise for a small private entity.BenzingaInsiders Buying ProtoKinetix And 2 Other Stocks Under $2 - PROTOKINETIX INC by ProtoKinetix, Inc. (OTC:PKThis Benzinga article reports on recent insider buying activity in three penny stocks: ProtoKinetix CFO Michael Guzzetta purchased 20,000 shares at approximately $0.02 per share for $330, Firsthand Technology Value Fund 10% owner Jeffrey Eberwein acquired 49,805 shares at $0.24 per share for $12,150, and RENN Fund President/CEO Murray Stahl bought 413 shares at $1.73 per share for $714. ProtoKinetix stock has declined roughly 53% over the past month, while Firsthand Technology Value Fund separately announced plans to seek stockholder approval to withdraw its BDC election and pursue liquidation. The article frames insider purchasing as a potential indicator for penny stock investors to consider.SecSEC FORM DProtoKinetix, Inc. filed a Form D with the Securities and Exchange Commission for an exempt offering of equity securities under Rule 506(b). The company has sold $429,000 of its total $500,000 offering target to eight investors as of December 30, 2022.